Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (PanGem)

Share this content:
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (PanGem)
 
Sponsors and Collaborators
Women and Infants Hospital of Rhode Island
Amgen
 
Contact
Carolyn M McCourt, MD
401-453-7520
 
Carol Berk, RN
401-453-7520
 
Investigator
Don S Dizon, MD
Women & Infants' Hospital
 
ClinicalTrials.gov Identifier

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs